Comparing Skin Conductance and Nol-index

November 6, 2020 updated by: Erasme University Hospital

Nociceptive Monitoring With Skin Conductance and Nol-index in Moderate-to-high Risk Cardiovascular Patients

Comparison of twà different nociception monitors during general anesthesia

Study Overview

Detailed Description

Analgesia remains a challenge in anesthesia. Several monitors have shown potential in detecting insufficient analgesia during general anesthesia, but they have not been investigated in patients undergoing cardiac and vascular surgery. In this study, we will compare skin conductance (Medstorm, Norway) and nol-index (Medasense, Israel) w during noxious and non-noxious stimuli. This study is carried out on patients included in another study (Nol-Index Guided Remifentanil Analgesia Versus Standard Analgesia During Moderate-to-High Risk Cardiovascular Surgery).

Study Type

Observational

Enrollment (Anticipated)

10

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Sean Coeckelenbergh, MD
  • Phone Number: 32 (0) 2 555 39 19
  • Email: secoecke@ulb.ac.be

Study Contact Backup

  • Name: Luc Barvais, MD, PhD
  • Phone Number: 32 (0) 2 555 39 19

Study Locations

      • Brussels, Belgium, 1070
        • Recruiting
        • Anesthesia Department, Erasme Hospital
        • Contact:
          • Sean Coeckelenbergh, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing cardiac or vascular surgery

Description

Inclusion Criteria:

  • moderate-to-high risk cardiac or vascular surgery
  • ASA 2-4

Exclusion Criteria:

  • chronic arrhythmia (e.g. atrial fibrillation)
  • aortic insufficiency
  • pacemaker
  • implanted defibrillator
  • valve surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients undergoing general anesthesia
Patients are monitored with Nol-Index, skin conductance, and antinociception-index
Multiparametric monitor that studies that establishes an index as a surrogate to nociception
Other Names:
  • PMD-200
Measures skin conductance as a surrogate to nociception
Other Names:
  • The PainMonitor Index

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nol-Index response
Time Frame: 1 to 2 hours
Nol-Index (diminsenliss value from 0 to 100) will be assessed during noxious and non noxious stimuli
1 to 2 hours
Skin conductance response
Time Frame: 1 to 2 hours
Peaks per second change during noxious and non noxious stimuli
1 to 2 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Luc Barvais, MD, PhD, Anesthesia Department, Erasme Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 20, 2019

Primary Completion (ACTUAL)

June 1, 2020

Study Completion (ANTICIPATED)

December 20, 2020

Study Registration Dates

First Submitted

October 23, 2019

First Submitted That Met QC Criteria

October 23, 2019

First Posted (ACTUAL)

October 25, 2019

Study Record Updates

Last Update Posted (ACTUAL)

November 9, 2020

Last Update Submitted That Met QC Criteria

November 6, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • P2019/427Am1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vascular Diseases

Clinical Trials on Nol-Index

3
Subscribe